Springhill Fund Asset Management (HK) Co Ltd
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Springhill Fund Asset Management (HK) Co Ltd reported 19 stock positions worth $20.9 million. Its top holding was Verona Pharma (VRNA) at 19.3% of the portfolio, followed by Summit Therapeutics (SMMT, 11.5%) and Janux Therapeutics (JANX, 10.2%). Compared with Q4 2024, it opened 13 new positions, sold out of 11, added to 2 and reduced 4. The biggest buy was a new position in Summit Therapeutics (SMMT) and the biggest sale an exit from Legend Biotech Corp.-ADR (LEGN).
- Most Recent 13F
- Q3 2025
- Location
- HONG KONG, K3
- CIK
- 0001911270
- Portfolio Value
- $20.9M (Q1 2025)
- SEC Filing
- 0001911270-25-000003 ↗ filed May 14, 2025
Holdings Value
Holdings 19 stocks · $20.9M
| VRNA Verona Pharma Ltd. | 19.32% | 63,499 | $4.0M | Reduce -53.1% |
| SMMT Summit Therapeutics Inc. | 11.49% | 124,307 | $2.4M | New |
| JANX Janux Therapeutics Inc. | 10.16% | 78,500 | $2.1M | Add +165.2% |
| REGN Regeneron Pharmaceuticals | 7.90% | 2,600 | $1.6M | New |
| NBIX Neurocrine Biosciences Inc. | 7.21% | 13,612 | $1.5M | New |
| INSM Insmed Inc. | 7.02% | 19,192 | $1.5M | Reduce -72.4% |
| SLNO Soleno Therapeutics Inc. | 6.80% | 19,858 | $1.4M | Add +1007.5% |
| JAZZ Jazz Pharmaceuticals PLC | 5.86% | 9,853 | $1.2M | New |
| AKRO Akero Therapeutics Inc. | 3.87% | 19,925 | $807K | Reduce -86.8% |
| ARGX Argenx SE - ADR | 3.25% | 1,146 | $678K | New |
| LLY Eli Lilly & Co. | 3.23% | 816 | $674K | New |
| PTGX Protagonist Therapeutics Inc. | 2.98% | 12,859 | $622K | New |
| TGTX TG Therapeutics Inc. | 2.55% | 13,500 | $532K | New |
| TARS Tarsus Pharmaceuticals Inc. | 1.74% | 7,076 | $363K | New |
| ASND Ascendis Pharma A/S | 1.62% | 2,173 | $339K | New |
| RYTM Rhythm Pharmaceuticals Inc. | 1.59% | 6,277 | $332K | New |
| BNTX Biontech SE-ADR | 1.31% | 3,000 | $273K | New |
| SWTX Springworks Therapeutics Inc. | 1.25% | 5,897 | $260K | New |
| COGT Cogent Biosciences Inc. | 0.85% | 29,491 | $177K | Reduce -94.6% |
Portfolio Sells Q4 2024 → Q1 2025
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −10.08 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −9.99 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −8.14 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −7.51 |
| COGT Cogent Biosciences Inc. | Reduce -94.6% | 0.85% | −6.10 |
| MRUS Merus NV | Sold out | 0.00% | −5.72 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −5.47 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −5.02 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −4.91 |
| DRUG Bright Minds Biosciences Inc. | Sold out | 0.00% | −3.55 |
| AKRO Akero Therapeutics Inc. | Reduce -86.8% | 3.87% | −2.97 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −2.65 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −2.47 |
| INSM Insmed Inc. | Reduce -72.4% | 7.02% | −0.78 |
| VRNA Verona Pharma Ltd. | Reduce -53.1% | 19.32% | +9.10 |
Portfolio Buys Q4 2024 → Q1 2025
| SMMT Summit Therapeutics Inc. | New | 11.49% | +11.49 |
| REGN Regeneron Pharmaceuticals | New | 7.90% | +7.90 |
| JANX Janux Therapeutics Inc. | Add +165.2% | 10.16% | +7.58 |
| NBIX Neurocrine Biosciences Inc. | New | 7.21% | +7.21 |
| SLNO Soleno Therapeutics Inc. | Add +1007.5% | 6.80% | +6.67 |
| JAZZ Jazz Pharmaceuticals PLC | New | 5.86% | +5.86 |
| ARGX Argenx SE - ADR | New | 3.25% | +3.25 |
| LLY Eli Lilly & Co. | New | 3.23% | +3.23 |
| PTGX Protagonist Therapeutics Inc. | New | 2.98% | +2.98 |
| TGTX TG Therapeutics Inc. | New | 2.55% | +2.55 |
| TARS Tarsus Pharmaceuticals Inc. | New | 1.74% | +1.74 |
| ASND Ascendis Pharma A/S | New | 1.62% | +1.62 |
| RYTM Rhythm Pharmaceuticals Inc. | New | 1.59% | +1.59 |
| BNTX Biontech SE-ADR | New | 1.31% | +1.31 |
| SWTX Springworks Therapeutics Inc. | New | 1.25% | +1.25 |